Catalent Starts Schorndorf Expansion

13.04.2023 - Catalent, a US-headquartered CDMO, has broken ground on a project in Schorndorf, Germany, that will add capacity for storing and handling clinical trial supply materials at controlled temperatures.

The investment of $20 million will also see the installation of a fully automatic bottle filling line plus a dedicated area for Catalent’s FastChain demand-led supply service. Work is expected to be completed by June 2024.

“Our site in Schorndorf plays a key strategic role in our global clinical supply network and this expansion will provide much needed capacity and capabilities to meet the growing needs of customers,” said Ricky Hopson, president, division head for clinical development & supply.

“Additional temperature-controlled handling, storage and distribution means the facility is well-equipped to respond to the growing demand for clinical supply capacity and services in the region, including for products requiring cold chain support,” Hopson said.

The Somerset, New Jersey-based CDMO has embarked on several expansion projects in the past year or so. In 2023 to date, the company has completed a $2.2 million expansion to its clinical supply facility in Singapore and opened a commercial-scale plasmid DNA manufacturing facility in Gosselies, Belgium.

Last year, Catalent also completed a series of projects at Morrisville Research Triangle Park in North Carolina, Bloomington, Indiana, Kansas City, Missouri, and Malvern, Pennsylvania, along with overseas investments in Limoges, France, Dartford, UK, and Shanghai, China.

Other projects announced last year are under way, including a $12 million program to increase cGMP analytical capabilities in Kansas City, establish a new biologics analytical center of excellence in Durham, North Carolina and expand capacity for oral dose forms in Winchester, Kentucky.

Author: Elaine Burridge, Freelance Journalist